

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following statements is true regarding progression-free survival (PFS) in the Phase III DESTINY-Breast03 trial, which compared trastuzumab deruxtecan (T-DXd) to trastuzumab emtansine (T-DM1) for patients with HER2-positive metastatic breast cancer after prior trastuzumab and taxane in the metastatic setting?
 - a. T-DM1 treatment resulted in significantly longer PFS
 - b. T-DXd treatment resulted in significantly longer PFS**
 - c. T-DXd treatment did not improve PFS for patients with brain metastases
 - d. No difference in PFS was observed between the treatment arms
2. Which of the following statements is true regarding invasive disease-free survival (iDFS) in the Phase III PALLAS study of endocrine therapy with or without palbociclib for patients with Stage II to Stage III hormone receptor (HR)-positive, HER2-negative breast cancer?
 - a. iDFS was improved with endocrine therapy and palbociclib
 - b. iDFS was improved with endocrine therapy alone
 - c. No difference in iDFS was observed between the treatment arms**
3. Which of the following statements is true regarding the Phase III monarchE study comparing abemaciclib with standard endocrine therapy to endocrine therapy alone for patients with high-risk HR-positive, HER2-negative localized breast cancer?
 - a. iDFS was improved with endocrine therapy and abemaciclib**
 - b. iDFS was improved with endocrine therapy alone
 - c. iDFS was improved with abemaciclib and endocrine therapy for only those patients with high Ki-67 expression
 - d. No difference in iDFS was observed between the treatment arms
4. Which of the following statements is true regarding PFS results from the Phase III EMERALD study, which compared the oral SERD (selective estrogen receptor degrader) elacestrant to an aromatase inhibitor or fulvestrant for patients with ER-positive, HER2-negative breast cancer?
 - a. No significant differences were detected between the treatment arms
 - b. PFS was better with elacestrant**
 - c. PFS was better with an aromatase inhibitor or fulvestrant